Anthera Pharmaceuticals(OTC) ANTH

Market CapN/A

Since IPO (2010)-100%

5 Year-100%

1 Year+0%

1 Month+0%

$0.00

+0.00%

+0.00Today

Anthera Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-09-03

Anthera Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-08-27
1 month	+0%	USD 0.00	2026-08-04
3 month	-99.9%	USD 0.00	2026-06-04
Year to date	-99%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-08-28
3 year	-99%	USD 0.00	2023-08-10
5 year	-100%	USD 0.02	2021-09-03
Since inception	-100%	USD 448.64	2010-03-01

Anthera Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.86M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

88.40 (High)

Dividend

$0.00

Beta (Volatility)

88.40 (High)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 4, 2025

Dividend

$0.00

Beta (Volatility)

88.40 (High)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 4, 2025

ANTH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company is advancing its pipeline, which includes Sollpura and Blisibimod, targeting critical health issues.

Products and Services

Sollpura: Investigational non-porcine pancreatic enzyme replacement therapy
Blisibimod: Targeting B-cell mediated autoimmune diseases
Licensing agreements with Amgen, Inc. and Eli Lilly and Company

Growth Outlook

Pipeline includes therapies in late-stage clinical trials
Focus on addressing significant unmet medical needs in healthcare
Potential for strategic partnerships to enhance development

Financial Highlights

Recent quarterly net income of -$7.72 million
Cash and cash equivalents of $8.09 million as of March 31, 2018
Trailing twelve months (TTM) revenue of $0

Anthera Pharmaceuticals operates in the biotechnology sector, with a focus on innovative treatments for serious health conditions. The company is currently advancing its clinical pipeline, which includes promising therapies that could address significant healthcare challenges. Recent financial data indicates a net loss, reflecting ongoing investments in research and development. The company maintains a solid cash position, which may support its continued operations and development efforts. With strategic partnerships and a focus on unmet medical needs, Anthera Pharmaceuticals presents an intriguing opportunity for potential investors interested in the biotechnology field.

AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Houston, TX 77002, US

ANTH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-485.59%

Return on Capital

N/A

Return on Assets

-461.07%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

26.18M

Volume

Avg. Volume

1.52K

Financials (TTM)

Gross Profit

-$28.26K

Operating Income

-$36.80M

EBITDA

-$36.40M

Operating Cash Flow

-$31.95M

Capital Expenditure

$0.00

Free Cash Flow

-$31.95M

Cash & ST Invst.

$8.09M

Total Debt

$0.00

Anthera Pharmaceuticals Performance Analysis

Anthera Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2017-06-30	N/A
Q3	2017-09-30	N/A
Q4	2017-12-31	N/A
Q1	2018-03-31	N/A

Anthera Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2017-06-30	153.2%
Q3	2017-09-30	-146.7%
Q4	2017-12-31	-76.7%
Q1	2018-03-31	73.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2018YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$7.47K

+3.0%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$4.43M

+62.1%

EBITDA

-$10.81M

-2.4%

Quarterly Fundamentals

Name

Q1 2018YOY CHG

Total Cash

$8.09M

-60.8%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-4.61%

N/A

Return on Invested Capital

35.10%

N/A

Free Cash Flow

-$9.38M

+34.5%

Operating Cash Flow

-$9.38M

+34.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PZRXQPhaseRx, Inc.

PZRXQPhaseRx, Inc.$0.00+0.00%

NTIINeurobiological Technologies, Inc.

NTIINeurobiological Technologies, Inc.$0.00+0.00%

SYVCSynovics Pharmaceuticals, Inc.

SYVCSynovics Pharmaceuticals, Inc.$0.00+0.00%

COTQFCotinga Pharmaceuticals Inc.

COTQFCotinga Pharmaceuticals Inc.$0.00+0.00%

SNNAQSienna Biopharmaceuticals, Inc.

SNNAQSienna Biopharmaceuticals, Inc.$0.00+0.00%

CMRAComera Life Sciences Holdings, Inc.

CMRAComera Life Sciences Holdings, Inc.$0.00+0.00%

SVSOSheerVision, Inc.

SVSOSheerVision, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.15-0.12%

NVDANvidia

NVDANvidia$230.36+0.01%

PATHUiPath

PATHUiPath$15.19-0.17%

INTCIntel

INTCIntel$95.80+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.13+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.74-0.02%

TSLATesla

TSLATesla$354.08-0.06%

Questions About ANTH

What is the current price of Anthera Pharmaceuticals?

Anthera Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Anthera Pharmaceuticals?

Over the past 52 weeks, Anthera Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Anthera Pharmaceuticals have?

Anthera Pharmaceuticals total debt is unavailable.

How much cash does Anthera Pharmaceuticals have on hand?

Anthera Pharmaceuticals does not have cash on hand data available.

What is Anthera Pharmaceuticals’s dividend yield?

Anthera Pharmaceuticals does not currently have a dividend yield.

Anthera Pharmaceuticals(OTC) ANTH

Anthera Pharmaceuticals Financials at a Glance

ANTH News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Anthera Pharmaceuticals

ANTH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Anthera Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ANTH

What is the current price of Anthera Pharmaceuticals?

What is the 52-week range for Anthera Pharmaceuticals?

How much debt does Anthera Pharmaceuticals have?

How much cash does Anthera Pharmaceuticals have on hand?

What is Anthera Pharmaceuticals’s dividend yield?

Premium Investing Services